Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

TD Cowen Maintains Outperform on BioLife Solns, Lowers Price Target to $25

Author: Benzinga Newsdesk | August 09, 2023 04:16pm
TD Cowen analyst Max Masucci maintains BioLife Solns (NASDAQ:BLFS) with a Outperform and lowers the price target from $29 to $25.

Posted In: BLFS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist